drugset / Trial / NCT00918164

Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects

NCT00918164

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to estimate the bioavailability of PF-04457845 tablets relative to solution and evaluate the effect of food (fasted vs. high fat meal) on the pharmacokinetics of an oral tablet formulation of PF-04457845

Timeline

Start
2009-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject REDAFAMDASTAT Small molecule 8 mg Oral

Indications

No indication recorded.